Background: Underdeployment and malapposition of stents during percutaneous coronary interventions (PCI) may lead to in-stent thrombosis and restenosis. Coronary angiography is limited for the analysis of the stent geometry and structure after deployment. Intravascular ultrasound remains the gold standard but its routine use is costly and time-consuming. StentBoost® (SB) is a new software developed by Philips Medical System®, which enhances stent visualization from a short digital cine run (30 frames /sec) acquired with a deflated balloon in place. SB allows a simple, real-time assessment of stent deployment.
Résults:
A total of 275 stents were implanted, 45% of them were drug eluting stents (DES). Direct stenting was performed in 78%. Results of SB and angiography were concordant for 209 lesions: 195 stents correctly deployed (75%) and 14 underdeployed (5%), detected by both techniques. In 47 patients (18%), SB detected an underdeployment of the stent whereas angiographic result was good. A post-dilatation was performed, on the basis of SB only, in 89% of these cases (vs 6% and 79% in the other groups, respectively). The additional contribution of SB was higher for left main lesions and for DES, and was not affected by coronary calcifications.
Conclusions:
This study confirmed the usefulness in current PCI practice of the stent visualization enhancement technique StentBoost®. SB revealed about 20% underdeployed stents not detected by conventional angiography, and allowed to optimize the procedure by ad hoc effective postdilatation. Background: Stenting is known to be more effective than balloon angioplasty in patients with small vessel coronary disease. However it is remains unclear if DES are more efficacious than BMS in this setting.
Methods:
From January 2004 to December 2008, all patients were treated with percutaneous coronary intervention and stenting in native small coronary vessels (defined as a reference vessel diameter <3 mm) were enrolled irrespective of indication. Patients were divided into two groups according to type of stent used: BMS group and DES group. Procedural and long-term clinical outcomes were compared between the both groups.
Results: A total of 645 patients were enrolled (368 treated with BMS, 277 with DES). Clinical follow up was obtained in 99.3% (median follow-up: 3.3±1.2 years; range to 12-60 months). At five years, patients treated with DES showed significantly higher five-year major adverse cardiac events (MACE) -free survival (HR 0.51, 95%CI 0.33-0.78, log-rank P=0,002) and target vessel revascularization (TVR) -free survival (HR 0.44, 95%CI 0.25-0.78, log-rank P=0,005). There were no significant differences between the two groups regarding death, acute myocardial infarction and peri proceduremyocardial infarction. The incidence of stent thrombosis was also similar in both groups.
Conclusions: DES is more effective than BMS in reducing MACE and TVR in small vessel disease. However, the use of BMS does not increase mortality or re infarction and so is reasonable to consider in selected cases.
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Objective: To evaluate the incidence, predictive factors, and prognosis of stent thrombosis in routine clinical practice.
Methods and results:
The study consisted in a retrospective cohort study involving 800 consecutive patients (mean age: 59.8+/-11. Stent thrombosis was a strong independent predictive factor of later mortality (HR:72.3; 95% CI [25.4-206 .1], p<0.0001).
Conclusion:
The incidence of stent thrombosis in our routine practice was substantially higher than the rates reported in clinical trials. ST was a serious complication affecting immediate and long term prognosis. Premature antiplatelet therapy discontinuation was incriminated in a great number of our patients due to the cost of this treatment.
